Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective upped by equities researchers at Morgan Stanley from $18.00 to $20.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price would suggest a potential upside of 35.04% from the stock’s current price.

Several other research analysts have also weighed in on the stock. Wells Fargo & Company lowered shares of Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $50.00 to $18.00 in a report on Thursday, September 3rd. William Blair lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 3rd. Evercore downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target on the stock. in a research note on Thursday, September 3rd. TD Cowen decreased their price target on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, September 3rd. Finally, Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Hold” and a consensus price target of $34.42.

Ultragenyx Pharmaceutical Trading Up 2.1%

Shares of NASDAQ:RARE traded up $0.31 on Friday, hitting $14.81. The company had a trading volume of 4,917,631 shares, compared to its average volume of 2,608,357. The company has a market cap of $1.46 billion, a PE ratio of -2.53 and a beta of 0.31. Ultragenyx Pharmaceutical has a 52-week low of $12.73 and a 52-week high of $39.89. The business has a 50 day moving average of $24.26 and a 200 day moving average of $24.49.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company’s quarterly revenue was up 28.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.17) earnings per share. As a group, equities analysts predict that Ultragenyx Pharmaceutical will post -3.98 EPS for the current year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RARE. BlackRock Inc. acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $355,746,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $6,397,000. Deutsche Bank AG acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $5,503,000. Corient Private Wealth LP bought a new stake in Ultragenyx Pharmaceutical during the second quarter worth approximately $4,644,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in Ultragenyx Pharmaceutical in the second quarter worth approximately $6,098,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: First FDA-approved Sanfilippo Type A treatment: FAYUVI is the first approved therapy for this fatal, ultra-rare neurodegenerative disease, creating a potentially significant new commercial opportunity for Ultragenyx. The company expects shipments to qualified treatment centers within 30–60 days. Reuters FDA approval article
• Positive Sentiment: Clinical and strategic benefits: Approval was supported by durable follow-up data, including an improvement versus natural history on cognitive measures. FAYUVI is Ultragenyx’s second gene therapy approval and sixth FDA approval; the company also received a Priority Review Voucher, which could accelerate a future drug candidate. Ultragenyx FAYUVI approval release
• Positive Sentiment: Analyst optimism increased: Citigroup raised its target to $32 and Canaccord Genuity and Cantor Fitzgerald each raised targets to $39. All three firms carry bullish ratings, implying substantial upside based on the stock’s recent trading level. Analyst price target changes
• Neutral Sentiment: Commercial execution will be important: FAYUVI’s roughly $3.95 million reported price highlights its revenue potential, but actual sales will depend on identifying eligible patients, insurance coverage, reimbursement, treatment-center capacity and manufacturing execution.
• Negative Sentiment: Safety and launch risks remain: FAYUVI carries warnings involving liver toxicity, low platelet counts, infusion reactions, possible thrombotic microangiopathy and malignancy risk. Long-term safety data and real-world adoption remain key uncertainties.
• Negative Sentiment: Overhangs persist: Recent coverage highlighted the impact of a failed Angelman syndrome trial, while Pomerantz announced an investigation on behalf of investors. Insider disclosures also showed selling rather than buying, which may temper sentiment.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.